Pharmaceutical Executive-09-13-2005

A look at the science behind a new class of rheumatoid arthritis drugs that act by suppressing an early stage of inflammation, the activation of T cells.

A University of California San Diego professor explains the results of his research on nuclear receptors and why these findings could lead to new therapies for autoimmune diseases.

Pharmaceutical Executive

Analysis of a new report that says safety-related product withdrawals have not increased since the approval process sped up in the 1990s.